These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 23981126

  • 1. Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention.
    Pattni SS, Brydon WG, Dew T, Johnston IM, Nolan JD, Srinivas M, Basumani P, Bardhan KD, Walters JR.
    Aliment Pharmacol Ther; 2013 Oct; 38(8):967-76. PubMed ID: 23981126
    [Abstract] [Full Text] [Related]

  • 2. Characterizing Factors Associated With Differences in FGF19 Blood Levels and Synthesis in Patients With Primary Bile Acid Diarrhea.
    Johnston IM, Nolan JD, Pattni SS, Appleby RN, Zhang JH, Kennie SL, Madhan GK, Jameie-Oskooei S, Pathmasrirengam S, Lin J, Hong A, Dixon PH, Williamson C, Walters JR.
    Am J Gastroenterol; 2016 Mar; 111(3):423-32. PubMed ID: 26856750
    [Abstract] [Full Text] [Related]

  • 3. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis.
    Walters JR, Tasleem AM, Omer OS, Brydon WG, Dew T, le Roux CW.
    Clin Gastroenterol Hepatol; 2009 Nov; 7(11):1189-94. PubMed ID: 19426836
    [Abstract] [Full Text] [Related]

  • 4. Biochemical Diagnosis of Bile Acid Diarrhea: Prospective Comparison With the 75Seleno-Taurohomocholic Acid Test.
    Borup C, Wildt S, Rumessen J, Graff J, Bouchelouche PN, Andersen TB, Vinter-Jensen L, Zaremba A, German Jørgensen SP, Gregersen T, Nøjgaard C, Timm HB, Rainteau D, Gauliard E, Munck LK.
    Am J Gastroenterol; 2020 Dec; 115(12):2086-2094. PubMed ID: 32740083
    [Abstract] [Full Text] [Related]

  • 5. Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea.
    Brydon WG, Nyhlin H, Eastwood MA, Merrick MV.
    Eur J Gastroenterol Hepatol; 1996 Feb; 8(2):117-23. PubMed ID: 8723414
    [Abstract] [Full Text] [Related]

  • 6. Diagnosis of bile acid diarrhoea by fasting and postprandial measurements of fibroblast growth factor 19.
    Borup C, Syversen C, Bouchelouche P, Damgaard M, Graff J, Rumessen JJ, Munck LK.
    Eur J Gastroenterol Hepatol; 2015 Dec; 27(12):1399-402. PubMed ID: 26426834
    [Abstract] [Full Text] [Related]

  • 7. 75SeHCAT scan in bile acid malabsorption in chronic diarrhoea.
    Mena Bares LM, Carmona Asenjo E, García Sánchez MV, Moreno Ortega E, Maza Muret FR, Guiote Moreno MV, Santos Bueno AM, Iglesias Flores E, Benítez Cantero JM, Vallejo Casas JA.
    Rev Esp Med Nucl Imagen Mol; 2017 Dec; 36(1):37-47. PubMed ID: 27765536
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid.
    Walters JR, Johnston IM, Nolan JD, Vassie C, Pruzanski ME, Shapiro DA.
    Aliment Pharmacol Ther; 2015 Jan; 41(1):54-64. PubMed ID: 25329562
    [Abstract] [Full Text] [Related]

  • 10. Serum Concentrations of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease.
    Battat R, Duijvestein M, Vande Casteele N, Singh S, Dulai PS, Valasek MA, Mimms L, McFarland J, Hester KD, Renshaw M, Jain A, Sandborn WJ, Boland BS.
    Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2722-2730.e4. PubMed ID: 30448597
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study.
    Appleby RN, Moghul I, Khan S, Yee M, Manousou P, Neal TD, Walters JRF.
    PLoS One; 2019 Dec; 14(1):e0211348. PubMed ID: 30682184
    [Abstract] [Full Text] [Related]

  • 13. SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis.
    Riemsma R, Al M, Corro Ramos I, Deshpande SN, Armstrong N, Lee YC, Ryder S, Noake C, Krol M, Oppe M, Kleijnen J, Severens H.
    Health Technol Assess; 2013 Dec; 17(61):1-236. PubMed ID: 24351663
    [Abstract] [Full Text] [Related]

  • 14. Serum 7 alpha-hydroxy-4-cholesten-3-one concentrations in the evaluation of bile acid malabsorption in patients with diarrhoea: correlation to SeHCAT test.
    Eusufzai S, Axelson M, Angelin B, Einarsson K.
    Gut; 1993 May; 34(5):698-701. PubMed ID: 8504974
    [Abstract] [Full Text] [Related]

  • 15. Effects of conventional and a novel colonic-release bile acid sequestrant, A3384, on fibroblast growth factor 19 and bile acid metabolism in healthy volunteers and patients with bile acid diarrhoea.
    Appleby RN, Bajor A, Gillberg PG, Graffner H, Simrén M, Ung KA, Walters J.
    United European Gastroenterol J; 2017 Apr; 5(3):380-388. PubMed ID: 28507750
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Incidence and predictive factors for positive 75SeHCAT test: improving the diagnosis of bile acid diarrhoea.
    Murray IA, Murray LK, Woolson KL, Sherfi H, Dixon I, Palmer J, Sulkin T.
    Scand J Gastroenterol; 2017 Apr; 52(6-7):698-703. PubMed ID: 28276822
    [Abstract] [Full Text] [Related]

  • 19. Defining primary bile acid diarrhea: making the diagnosis and recognizing the disorder.
    Walters JR.
    Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):561-7. PubMed ID: 20932141
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.